Format

Send to

Choose Destination
Nat Rev Drug Discov. 2004 Dec;3(12):1001-10.

Strategies to overcome resistance to targeted protein kinase inhibitors.

Author information

1
Axxima Pharmaceuticals AG, Max-Lebsche-Platz 32, 81377 M√ľnchen, Germany. henrik.daub@axxima.com

Abstract

Selective inhibition of protein tyrosine kinases is gaining importance as an effective therapeutic approach for the treatment of a wide range of human cancers. However, as extensively documented for the BCR-ABL oncogene in imatinib-treated leukaemia patients, clinical resistance caused by mutations in the targeted oncogene has been observed. Here, we look at how structural and mechanistic insights from imatinib-insensitive Bcr-Abl have been exploited to identify second-generation drugs that override acquired target resistance. These insights have created a rationale for the development of either multi-targeted protein kinase inhibitors or cocktails of selective antagonists as antitumour drugs that combine increased therapeutic potency with a reduced risk of the emergence of molecular resistance.

PMID:
15573099
DOI:
10.1038/nrd1579
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Nature Publishing Group
Loading ...
Support Center